-
1
-
-
0024490334
-
Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma
-
Ahmann DL, Creagan ET, Hahn RG, Edmonson JH, Bisel HF, Schaid DJ. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989;63:224-7.
-
(1989)
Cancer
, vol.63
, pp. 224-227
-
-
Ahmann, D.L.1
Creagan, E.T.2
Hahn, R.G.3
Edmonson, J.H.4
Bisel, H.F.5
Schaid, D.J.6
-
2
-
-
0032858487
-
Phase III multicenter randomized trial of the Dartmouth Regimen versus dacarbazine in patients with metastatic melanoma
-
Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III multicenter randomized trial of the Dartmouth Regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-51.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2745-2751
-
-
Chapman, P.B.1
Einhorn, L.H.2
Meyers, M.L.3
Saxman, S.4
Destro, A.N.5
Panageas, K.S.6
Begg, C.B.7
Agarwala, S.S.8
Schuchter, L.M.9
Ernstoff, M.S.10
Houghton, A.N.11
Kirkwood, J.M.12
-
3
-
-
0029086370
-
Prognostic factors in 1,521 melanoma patients with distant metastasis
-
Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastasis. J Am Coll Surg 1995;181:193-201.
-
(1995)
J Am Coll Surg
, vol.181
, pp. 193-201
-
-
Barth, A.1
Wanek, L.A.2
Morton, D.L.3
-
4
-
-
0031805726
-
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa and interleukin-2 for patients with metastatic melanoma
-
Bedikian A, Buzaid AC, Plager C, Papadopoulos N, Legha SA, Ring S, Eton O. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:1752-9.
-
(1998)
J Clin Oncol
, vol.16
, pp. 1752-1759
-
-
Bedikian, A.1
Buzaid, A.C.2
Plager, C.3
Papadopoulos, N.4
Legha, S.A.5
Ring, S.6
Eton, O.7
-
5
-
-
0000709971
-
Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinbastine, temozolomide (CVT), interleukin-2 (IL-2) and interferon α-2b (IFN) in patients with metastatic melanoma
-
Atkins M, Gollob JA, Mier JW, McDermott DF, Tutin L, Sorokin P, Sosman JA. Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinbastine, temozolomide (CVT), interleukin-2 (IL-2) and interferon α-2b (IFN) in patients with metastatic melanoma. Proc ASCO 1998;17:507. Proc ASCO 2001. Abstract 1391.
-
(1998)
Proc ASCO
, vol.17
, pp. 507
-
-
Atkins, M.1
Gollob, J.A.2
Mier, J.W.3
McDermott, D.F.4
Tutin, L.5
Sorokin, P.6
Sosman, J.A.7
-
6
-
-
0042394339
-
-
Abstract 1391
-
Atkins M, Gollob JA, Mier JW, McDermott DF, Tutin L, Sorokin P, Sosman JA. Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinbastine, temozolomide (CVT), interleukin-2 (IL-2) and interferon α-2b (IFN) in patients with metastatic melanoma. Proc ASCO 1998;17:507. Proc ASCO 2001. Abstract 1391.
-
(2001)
Proc ASCO
-
-
-
7
-
-
0032850026
-
Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
-
O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J Clin Oncol 1999;17:2752-61.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2752-2761
-
-
O'Day, S.J.1
Gammon, G.2
Boasberg, P.D.3
Martin, M.A.4
Kristedja, T.S.5
Guo, M.6
Stern, S.7
Edwards, S.8
Fournier, P.9
Weisberg, M.10
Cannon, M.11
Fawzy, N.W.12
-
8
-
-
0033024863
-
High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated from 1985-1993
-
Atkins MB, Lotze M, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated from 1985-1993. J Clin Oncol 1999;17:2105-16.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2105-2116
-
-
Atkins, M.B.1
Lotze, M.2
Dutcher, J.P.3
Fisher, R.I.4
Weiss, G.5
Margolin, K.6
Abrams, J.7
Sznol, M.8
Parkinson, D.9
Hawkins, M.10
Paradise, C.11
Kunkel, L.12
-
9
-
-
0033848628
-
High-dose aldesleukin therapy in patients with metastatic melanoma: Long-term survival update
-
Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose aldesleukin therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6:S11-S14.
-
(2000)
Cancer J Sci Am
, vol.6
-
-
Atkins, M.B.1
Kunkel, L.2
Sznol, M.3
Rosenberg, S.A.4
-
10
-
-
0031890206
-
Immunologic and therapeutic evaluation of a synthetic vaccine for the treatment of patients with metastatic melanoma
-
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola M, Topalian L, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, et al. Immunologic and therapeutic evaluation of a synthetic vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
-
(1998)
Nat Med
, vol.4
, pp. 321-327
-
-
Rosenberg, S.A.1
Yang, J.C.2
Schwartzentruber, D.J.3
Hwu, P.4
Marincola, M.5
Topalian, L.6
Restifo, N.P.7
Dudley, M.E.8
Schwarz, S.L.9
Spiess, P.J.10
Wunderlich, J.R.11
Parkhurst, M.R.12
-
11
-
-
0026303386
-
Attempts to optimize specific immunotherapy for melanoma
-
Mitchell MS: Attempts to optimize specific immunotherapy for melanoma. Int Rev Immunol 1991;7:331-47.
-
(1991)
Int Rev Immunol
, vol.7
, pp. 331-347
-
-
Mitchell, M.S.1
-
12
-
-
0027248953
-
Active specific immunotherapy of melanoma with allogeneic cell lysates: Rationale, results and possible mechanisms of action
-
Mitchell MS, Harel W, Kan-Mitchell J, LeMay LG, Goedegebuure P, Huang XQ, Hofman F, Groshen S. Active specific immunotherapy of melanoma with allogeneic cell lysates: rationale, results and possible mechanisms of action. Ann NY Acad Sci 1993;690:153-66.
-
(1993)
Ann NY Acad Sci
, vol.690
, pp. 153-166
-
-
Mitchell, M.S.1
Harel, W.2
Kan-Mitchell, J.3
LeMay, L.G.4
Goedegebuure, P.5
Huang, X.Q.6
Hofman, F.7
Groshen, S.8
-
13
-
-
0031648808
-
Perspective on allogeneic melanoma lysates in active specific immunotherapy
-
Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998;25:623-5.
-
(1998)
Semin Oncol
, vol.25
, pp. 623-625
-
-
Mitchell, M.S.1
-
14
-
-
0025147441
-
Treatment of metastatic melanoma with an autologous tumor-cell vaccine. Clinical and immunologic results in 64 patients
-
Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine. Clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858-67.
-
(1990)
J Clin Oncol
, vol.8
, pp. 1858-1867
-
-
Berd, D.1
Maguire H.C., Jr.2
McCue, P.3
Mastrangelo, M.J.4
-
15
-
-
0030986643
-
Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases
-
Berd D, Maguire HC Jr, Schucter LM, Mastrangelo MJ, Hauck WW, Sato T, Mastrangelo MJ. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997;15:2359-70.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2359-2370
-
-
Berd, D.1
Maguire H.C., Jr.2
Schucter, L.M.3
Mastrangelo, M.J.4
Hauck, W.W.5
Sato, T.6
Mastrangelo, M.J.7
-
16
-
-
0026802163
-
Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
-
Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:463-82.
-
(1992)
Ann Surg
, vol.216
, pp. 463-482
-
-
Morton, D.L.1
Foshag, L.J.2
Hoon, D.S.3
Nizze, J.A.4
Famatiga, E.5
Wanek, L.A.6
Chang, C.7
Davtyan, D.G.8
Gupta, R.K.9
Elashoff, R.10
-
17
-
-
0033991158
-
Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance
-
Marincola FM, Jaffe EM, Hicklin DJ, Jaffee E, M.Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
-
(2000)
Adv Immunol
, vol.74
, pp. 181-273
-
-
Marincola, F.M.1
Jaffe, E.M.2
Hicklin, D.J.3
Jaffee, E.M.4
Hicklin, D.J.5
Ferrone, S.6
-
18
-
-
0035889708
-
Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: Regression of pulmonary metastasis
-
Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastasis. Int J Cancer 2001;94:531-9.
-
(2001)
Int J Cancer
, vol.94
, pp. 531-539
-
-
Berd, D.1
Sato, T.2
Cohn, H.3
Maguire H.C., Jr.4
Mastrangelo, M.J.5
-
19
-
-
0030057341
-
Vaccine therapy for malignant melanoma
-
Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996;46:225-44.
-
(1996)
CA Cancer J Clin
, vol.46
, pp. 225-244
-
-
Morton, D.L.1
Barth, A.2
-
20
-
-
0031713904
-
Correlation of specific immune responses with survival in melanoma patients with distant metastasis receiving polyvalent melanoma cell vaccine
-
Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastasis receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16:2913-20.
-
(1998)
J Clin Oncol
, vol.16
, pp. 2913-2920
-
-
Hsueh, E.C.1
Gupta, R.K.2
Qi, K.3
Morton, D.L.4
-
22
-
-
0003708810
-
-
Oxford: Oxford University Press
-
Leukocyte Typing IV, Knapp W. et al., eds. Oxford: Oxford University Press, 1989.
-
(1989)
Leukocyte Typing IV
-
-
Knapp, W.1
-
23
-
-
0025602141
-
Involvement of the CDw50 molecule in allorecognition
-
Vilella R, Milà J, Lozano F, Alberola-Ila J, Places L, Vives J. Involvement of the CDw50 molecule in allorecognition. Tissue Antigens 1990;36:203-10.
-
(1990)
Tissue Antigens
, vol.36
, pp. 203-210
-
-
Vilella, R.1
Milà, J.2
Lozano, F.3
Alberola-Ila, J.4
Places, L.5
Vives, J.6
-
25
-
-
0030942666
-
Altered immune responses in interleukin 10 transgenic mice
-
Hagenbaugh A, Sharma S, Dubinett SM, Wei SH, Aranda R, Cheroutre H, Fowell DJ, Binder S, Tsao B, Locksley RM, Moore KW, Kronenberg M, et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med 1997;185:2101-10.
-
(1997)
J Exp Med
, vol.185
, pp. 2101-2110
-
-
Hagenbaugh, A.1
Sharma, S.2
Dubinett, S.M.3
Wei, S.H.4
Aranda, R.5
Cheroutre, H.6
Fowell, D.J.7
Binder, S.8
Tsao, B.9
Locksley, R.M.10
Moore, K.W.11
Kronenberg, M.12
-
26
-
-
0033557968
-
Tumor-induced interleukin-10 inhibits type I immune responses directed at a tumor antigen as well as a nontumor antigen present at the tumor site
-
Halak BK, Maguire Jr HC, Lattime EC. Tumor-induced interleukin-10 inhibits type I immune responses directed at a tumor antigen as well as a nontumor antigen present at the tumor site. Cancer Res 1999;59:911-7.
-
(1999)
Cancer Res
, vol.59
, pp. 911-917
-
-
Halak, B.K.1
Maguire H.C., Jr.2
Lattime, E.C.3
-
27
-
-
0033105695
-
Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells
-
Steinbrink K, Jonuleit H, Müller G, Schuler G, Knop J, Enk A. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood 1999;93:1634-42.
-
(1999)
Blood
, vol.93
, pp. 1634-1642
-
-
Steinbrink, K.1
Jonuleit, H.2
Müller, G.3
Schuler, G.4
Knop, J.5
Enk, A.6
-
28
-
-
0036134856
-
Cutting edge: IL-10-producing CD4+ T cells mediate tumor rejection
-
Segal BM, Glass DD, Shevach EM. Cutting edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol 2002;168:1-4.
-
(2002)
J Immunol
, vol.168
, pp. 1-4
-
-
Segal, B.M.1
Glass, D.D.2
Shevach, E.M.3
|